Cytokinetics Company Profile (NASDAQ:CYTK)

About Cytokinetics

Cytokinetics logoCytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYTK
  • CUSIP:
Key Metrics:
  • Previous Close: $12.23
  • 50 Day Moving Average: $11.11
  • 200 Day Moving Average: $8.58
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.37
  • P/E Growth: -0.62
  • Market Cap: $485.57M
  • Outstanding Shares: 39,703,000
  • Beta: 1.34
Additional Links:
Companies Related to Cytokinetics:

Analyst Ratings

Consensus Ratings for Cytokinetics (NASDAQ:CYTK) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.14 (56.52% upside)

Analysts' Ratings History for Cytokinetics (NASDAQ:CYTK)
Show:
DateFirmActionRatingPrice TargetDetails
8/18/2016Roth CapitalReiterated RatingBuy$22.00View Rating Details
8/2/2016JMP SecuritiesReiterated RatingBuy$17.00View Rating Details
7/27/2016Needham & Company LLCBoost Price TargetBuy$15.00 -> $17.00View Rating Details
7/13/2016FBR & CoReiterated RatingOutperform$24.00View Rating Details
7/12/2016Piper Jaffray Cos.Reiterated RatingOverweight$24.00View Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details
2/17/2016Cowen and CompanyReiterated RatingBuy$16.00View Rating Details
7/24/2015MLV & Co.Reiterated RatingBuy$9.00 -> $14.00View Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for Cytokinetics (NASDAQ:CYTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016        
7/28/2016Q2($0.28)($0.29)ViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)ViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
4/30/2015Q1($0.12)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)ViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytokinetics (NASDAQ:CYTK)
Current Year EPS Consensus Estimate: $-1.30 EPS
Next Year EPS Consensus Estimate: $-1.66 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.33)($0.33)($0.33)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.42)($0.42)($0.42)
Q4 20161($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytokinetics (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cytokinetics (NASDAQ:CYTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cytokinetics (NASDAQ:CYTK)
DateHeadline
rttnews.com logoJNP Will Bleed On Failed Trial, CERU Crashes, CYTK Progresses With VITALITY (NASDAQ:CYTK)
www.rttnews.com - August 18 at 4:35 PM
streetinsider.com logoCytokinetics (CYTK) Announces Completion of VITALITY-ALS Patient Enrollment (NASDAQ:CYTK)
www.streetinsider.com - August 18 at 4:35 PM
streetinsider.com logoCytokinetics (CYTK) Announces Completion of VITALITY-ALS Patient Enrollment - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - August 18 at 9:13 AM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 8-K, Other Events (NASDAQ:CYTK)
biz.yahoo.com - August 17 at 8:50 AM
publicnow.com logoCytokinetics Completes Enrollment in VITALITY-ALS, Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS (NASDAQ:CYTK)
www.publicnow.com - August 17 at 8:50 AM
finance.yahoo.com logoCYTOKINETICS INC Financials (NASDAQ:CYTK)
finance.yahoo.com - August 12 at 4:34 PM
capitalcube.com logoETF’s with exposure to Cytokinetics, Inc. : August 11, 2016 (NASDAQ:CYTK)
www.capitalcube.com - August 11 at 4:39 PM
capitalcube.com logoCytokinetics, Inc. :CYTK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:CYTK)
www.capitalcube.com - August 10 at 4:39 PM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:CYTK)
biz.yahoo.com - August 4 at 10:16 PM
News IconThese Biotech’s are Due for a Run (NASDAQ:CYTK)
www.ssuchronicle.com - August 4 at 4:47 PM
finance.yahoo.com logoCytokinetics (CYTK) Shares March Higher, Can It Continue? (NASDAQ:CYTK)
finance.yahoo.com - August 4 at 4:47 PM
smarteranalyst.com logoJMP Securities Bullish on Cytokinetics, Inc. (CYTK) Following 2Q Update; Sees Key Catalysts on Track - Smarter Analyst (NASDAQ:CYTK)
www.smarteranalyst.com - August 2 at 9:20 AM
istreetwire.com logoStocks To Watch: Intrexon Corporation (XON), Cytokinetics, Incorporated (CYTK), Alder Biopharmaceuticals Inc. (ALDR) - iStreetWire (NASDAQ:CYTK)
istreetwire.com - August 1 at 4:29 PM
4-traders.com logoCytokinetics : reports 2Q loss (NASDAQ:CYTK)
www.4-traders.com - July 29 at 9:54 PM
streetinsider.com logoCytokinetics (CYTK), Astellas Pharma Expand Colaboration into ALS (NASDAQ:CYTK)
www.streetinsider.com - July 29 at 9:54 PM
News IconBiotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More - Xconomy (NASDAQ:CYTK)
www.xconomy.com - July 29 at 4:37 PM
ftsenews.co.uk logoNeedham reiterated Cytokinetics Inc (NASDAQ:CYTK) as 'Buy' With 17 PT - FTSE News (NASDAQ:CYTK)
www.ftsenews.co.uk - July 29 at 4:37 PM
seekingalpha.com logoCytokinetics's (CYTK) CEO Robert Blum on Q2 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:CYTK)
seekingalpha.com - July 29 at 8:24 AM
globenewswire.com logoCytokinetics, Inc. Reports Second Quarter 2016 Financial Results ... - GlobeNewswire (press release) (NASDAQ:CYTK)
globenewswire.com - July 29 at 8:24 AM
streetinsider.com logoCytokineti cs(CYTK) Notches New Milestone with Expanded Astellas Partnership - Roth Capital (NASDAQ:CYTK)
www.streetinsider.com - July 28 at 5:36 PM
globenewswire.com logoCytokinetics, Inc. Reports Second Quarter 2016 Financial Results (NASDAQ:CYTK)
globenewswire.com - July 28 at 5:36 PM
sg.finance.yahoo.com logoCytokinetics reports 2Q loss (NASDAQ:CYTK)
sg.finance.yahoo.com - July 28 at 5:21 PM
biz.yahoo.com logoQ2 2016 Cytokinetics Inc Earnings Release - 4:00 pm ET (NASDAQ:CYTK)
biz.yahoo.com - July 28 at 7:07 AM
globenewswire.com logoCytokinetics and Astellas Announce Option Right for Tirasemtiv and Expansion of Global Collaboration for CK ... - GlobeNewswire (press release) (NASDAQ:CYTK)
globenewswire.com - July 27 at 4:40 PM
publicnow.com logoCytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS (NASDAQ:CYTK)
www.publicnow.com - July 27 at 1:28 PM
streetinsider.com logoCytokinetics (CYTK), Astellas Pharma Expand Colaboration into ALS - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - July 27 at 11:13 AM
bizjournals.com logoWith latest swing, Peninsula biotech tries to double up Lou Gehrig's disease (NASDAQ:CYTK)
feeds.bizjournals.com - July 27 at 9:48 AM
publicnow.com logoCytokinetics and Astellas Announce Option Right for Tirasemtiv and Expansion of Global Collaboration for CK-2127107 in ALS (NASDAQ:CYTK)
www.publicnow.com - July 27 at 7:58 AM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:CYTK)
biz.yahoo.com - July 27 at 7:35 AM
News IconBiotech Firms Fighting Cancer (NASDAQ:CYTK)
www.ssuchronicle.com - July 25 at 3:48 PM
equities.com logoCytokinetics Looking for Higher Pricing after ALS Drug is Approved - Equities.com (NASDAQ:CYTK)
www.equities.com - July 24 at 4:21 PM
News IconCytokinetics, Incorporated (NASDAQ:CYTK): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:CYTK)
www.engelwooddaily.com - July 20 at 5:42 PM
News IconCytokinetics (NASDAQ:CYTK) Sellers Increased By 10.66% Their Shorts - Consumer Eagle (NASDAQ:CYTK)
www.consumereagle.com - July 20 at 9:52 AM
investorplace.com logo5 Biotechnology Stocks to Buy Now - Investorplace.com (NASDAQ:CYTK)
investorplace.com - July 18 at 4:39 PM
News IconCytokinetics, Inc.'s Trend Down, Especially After Today's Weak Session - Consumer Eagle (NASDAQ:CYTK)
www.consumereagle.com - July 15 at 8:52 AM
publicnow.com logoCytokinetics to Announce Second Quarter Results on July 28, 2016 (NASDAQ:CYTK)
www.publicnow.com - July 14 at 4:18 PM
News IconHow Analysts Feel About Cytokinetics, Inc. (NASDAQ:CYTK)? - Consumer Eagle (NASDAQ:CYTK)
www.consumereagle.com - July 14 at 7:17 AM
smarteranalyst.com logoPiper Jaffray Analyst Bullish on Cytokinetics, Inc. (CYTK) - Smarter Analyst (NASDAQ:CYTK)
www.smarteranalyst.com - July 13 at 4:38 PM
streetinsider.com logoCytokinetics (CYTK) Pipeline Progress to Be Seen in the 2nd-Half - Piper Jaffray - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - July 12 at 8:52 AM
News IconCytokinetics (NASDAQ:CYTK) Sellers Covered 1.77% of Their Shorts - Press Telegraph (NASDAQ:CYTK)
presstelegraph.com - July 12 at 8:52 AM
investornewswire.com logoIs $24 Within Reach For Cytokinetics, Incorporated (NASDAQ:CYTK)? - Investor Newswire (NASDAQ:CYTK)
www.investornewswire.com - July 7 at 4:33 PM
kcregister.com logoPNM Resources, Inc. (NYSE:PNM) Fell -0.56%: Cytokinetics, Incorporated (NASDAQ:CYTK), Kearny Financial Corp ... - KC Register (NASDAQ:CYTK)
www.kcregister.com - July 6 at 4:36 PM
fiscalstandard.com logoBroker Outlook For Cytokinetics, Incorporated (NASDAQ:CYTK) - Fiscal Standard (NASDAQ:CYTK)
www.fiscalstandard.com - July 6 at 4:36 PM
globenewswire.com logoCytokinetics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - GlobeNewswire (press release) (NASDAQ:CYTK)
globenewswire.com - July 6 at 4:36 PM
publicnow.com logoCytokinetics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference (NASDAQ:CYTK)
www.publicnow.com - July 5 at 4:21 PM
fiscalstandard.com logoBroker Outlook For The Week Ahead Cytokinetics, Incorporated (NASDAQ:CYTK) - Fiscal Standard (NASDAQ:CYTK)
www.fiscalstandard.com - July 4 at 4:20 PM
seekingalpha.com logoCytokinetics commences mid-stage study to assess effect of CK-2127107 on physical function in COPD patients - Seeking Alpha (NASDAQ:CYTK)
seekingalpha.com - July 1 at 4:32 PM
smarteranalyst.com logoAnalysts Dive Into Endo International plc – Ordinary Shares (ENDO) and Cytokinetics, Inc. (CYTK) With Different Views - Smarter Analyst (NASDAQ:CYTK)
www.smarteranalyst.com - July 1 at 4:32 PM
finance.yahoo.com logoCytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease (NASDAQ:CYTK)
finance.yahoo.com - June 30 at 4:49 PM
streetinsider.com logoCytokinetics (CYTK) Commences CK-107 Crossover Trial in COPD - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - June 30 at 10:04 AM

Social

Cytokinetics (NASDAQ:CYTK) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff